Trial Search Results
Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells
The purpose of this study is to assess long-term side effects from subjects who receive an Adicet Bio γδ CAR T cell product. Subjects will join this study once they complete the parent interventional study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study. For a period of 15 years from the first administration of Adicet Bio allogeneic γδ CAR T cell product, subjects will be assessed for long-term safety and survival through collection of data that include safety, efficacy, pharmacokinetics and immunogenicity.
Stanford is currently not accepting patients for this trial.
Adicet Bio, Inc
- Genetic: ADI-001
- All patients who received any Adicet allogeneic CAR T investigational product and have
either completed the core treatment protocol or have discontinued early
- All patients who are willing and able to adhere to the study visit schedule and other
- Capable of giving signed informed consent which includes compliance with requirements
and restrictions listed in the informed consent form (ICF) and protocol
- There are no specific exclusion criteria for this study
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study